Equities Analysts Offer Predictions for FMS Q4 Earnings

Fresenius Medical Care AG (NYSE:FMS) – Investment analysts at Zacks Research raised their Q4 2026 EPS estimates for Fresenius Medical Care in a report issued on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings per share of $0.62 for the quarter, up from their prior estimate of $0.61. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share.

Several other equities research analysts have also recently weighed in on FMS. Berenberg Bank started coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target for the company. Truist Financial increased their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, StockNews.com started coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They set a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Stock Down 2.2 %

Shares of NYSE FMS opened at $22.15 on Thursday. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $24.31. The firm has a market capitalization of $13.00 billion, a price-to-earnings ratio of 18.31, a PEG ratio of 0.96 and a beta of 0.93. The stock has a 50 day moving average price of $22.21 and a 200 day moving average price of $20.64. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of Fresenius Medical Care by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock worth $211,000 after acquiring an additional 1,528 shares during the last quarter. Franklin Resources Inc. grew its position in Fresenius Medical Care by 3.3% during the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after purchasing an additional 2,386 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Fresenius Medical Care during the 3rd quarter valued at approximately $38,000. MML Investors Services LLC raised its holdings in shares of Fresenius Medical Care by 5.3% in the third quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after buying an additional 753 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in shares of Fresenius Medical Care by 70.8% during the third quarter. XTX Topco Ltd now owns 39,769 shares of the company’s stock worth $847,000 after buying an additional 16,487 shares during the period. 8.37% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.